Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Blinatumomab + CF33-CD19t |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Blinatumomab | Blincyto | anti-CD19/anti-CD3 recombinant bispecific|monoclonal antibody MT103|MEDI-538 | CD19 Antibody 20 | Blincyto (blinatumomab) is a bispecific antibody that binds both CD19 on B-cells and the CD3 complex on T-cells, therefore facilitates T-cell mediated killing of CD19-expressing tumor cells (PMID: 26337639). Blincyto (blinatumomab) is FDA approved for the treatment of B-cell precursor acute lymphoblastic leukemia in adult and children negative for BCR-ABL1 (FDA.gov). |
CF33-CD19t | onCARlytics | CF33-CD19t is an oncolytic vaccinia virus that delivers a truncated CD19 antigen to tumor cells, potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06063317 | Phase I | CF33-CD19t Blinatumomab + CF33-CD19t | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (OASIS) | Recruiting | USA | 0 |